SCHEMBL29907396

SCHEMBL29907396

C[C@@H](O)c1cc(C(=O)Nc2ccc(OC(F)F)cc2)c(=O)n(-c2ccccc2OCC(F)(F)F)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
PAX8 Q06710 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
S1PR1 P21453 1/20 0.41
SCN8A Q9UQD0 2/20 0.38
SCN10A Q9Y5Y9 2/20 0.38
KCNK3 O14649 1/20 0.38
KCNK9 Q9NPC2 1/20 0.38
THRB P10828 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29601498 0.88 UGCG (0.55) UGCGSMN1; SMN2NPSR1MAPTMEN1
SCHEMBL29907503 0.87 UGCG (0.60) UGCGSMN1; SMN2NPSR1MAPTMEN1
SCHEMBL29907406 0.85 UGCG (0.52) UGCGSMN1; SMN2NPSR1MAPTMEN1
SCHEMBL29907634 0.76 UGCG (0.76) UGCGKDM4EMET
SCHEMBL29907410 0.76 UGCG (0.75) UGCGSMN1; SMN2MAPTTHRBMET
SCHEMBL29907490 0.76 UGCG (0.75) UGCGSMN1; SMN2MAPTS1PR1THRB
SCHEMBL29907628 0.73 UGCG (0.61) UGCGSMN1; SMN2MAPTS1PR1THRB
SCHEMBL29907407 0.73 UGCG (0.61) UGCGSMN1; SMN2MAPTLMNAS1PR1
SCHEMBL29907563 0.72 TSHR (0.45) UGCGMAPTMETRECQL
SCHEMBL29907394 0.71 UGCG (0.82) UGCGSMN1; SMN2NPSR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC UGCG 10/4885SMN1; SMN2 71/4885NPSR1 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.